Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Date
2020-06-18Author
Robbiani, Davide F
Gaebler, Christian
Muecksch, Frauke
Lorenzi, Julio C C
Wang, Zijun
Cho, Alice
Agudelo, Marianna
Barnes, Christopher O
Gazumyan, Anna
Finkin, Shlomo
Hägglöf, Thomas
Oliveira, Thiago Y
Viant, Charlotte
Hurley, Arlene
Hoffmann, Hans-Heinrich
Millard, Katrina G
Kost, Rhonda G
Cipolla, Melissa
Gordon, Kristie
Bianchini, Filippo
Chen, Spencer T
Ramos, Victor
Patel, Roshni
Dizon, Juan
Shimeliovich, Irina
Mendoza, Pilar
Hartweger, Harald
Nogueira, Lilian
Pack, Maggi
Horowitz, Jill
Schmidt, Fabian
Weisblum, Yiska
Michailidis, Eleftherios
Ashbrook, Alison W
Waltari, Eric
Pak, John E
Huey-Tubman, Kathryn E
Koranda, Nicholas
Hoffman, Pauline R
West, Anthony P
Rice, Charles M
Hatziioannou, Theodora
Bjorkman, Pamela J
Bieniasz, Paul D
Caskey, Marina
Nussenzweig, Michel C
Metadata
Show full item record
Documentos PDF
Summary in foreign language
During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21–5. Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres: less than 1:50 in 33% and below 1:1,000 in 79%, while only 1% showed titres above 1:5,000. Antibody sequencing revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50 values) as low as single digit nanograms per millitre. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Link to resource
https://www.nature.com/articles/s41586-020-2456-9Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.